<DOC>
	<DOCNO>NCT02519543</DOCNO>
	<brief_summary>In previous study Dr. Calkin , principal investigator study , person bipolar disorder either type II diabetes insulin resistance find experience severe symptom bipolar illness lower response treatment , compare person bipolar disorder type II diabetes insulin resistance . To explore finding , investigator develop study see add metformin , drug use improve body 's use insulin , may also help improve symptom bipolar illness .</brief_summary>
	<brief_title>Treating Insulin Resistance Strategy Improve Outcome Refractory Bipolar Disorder</brief_title>
	<detailed_description>This 26-week randomized , double-blind , parallel group prospective study efficacy metformin add-on treatment patient insulin resistance ( IR ) non-remitting bipolar illness , conduct three year . The investigator compare effect metformin versus placebo outcome patient , current optimize mood stabilize treatment usual ( TAU , accord Canadian Network Mood Anxiety Treatments [ CANMAT ] American Psychiatric Association ( APA ) guideline ) remain unchanged period least 8 week prior throughout study . Patients undergo baseline assessment randomize treatment placebo metformin titration full dose 2 week . Patients remain full treatment 24 week thereafter ( total trial duration 26 week patient ) . The investigator compare response metformin versus placebo ( measure Montgomery-Çºsberg Depression Rating Scale [ MADRS ] primary outcome ) . Subjects : Enrolment 110 subject IR non-remitting bipolar depression recruit three year 2 site , primary site Halifax , Nova Scotia , Canada second site Pittsburgh , Pennsylvania , USA .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . 18 year age old 2. diagnosis BD I II 3. nonremitting BD define presence mood symptom least moderate severity , indicate MADRS score &gt; 15 despite optimal treatment accord CANMAT/APA guideline 4 . HOMAIR &gt; 1.8 , indicate IR ( subject haveFasting PLasma Glucose ( FPG ) Fasting Serum Insulin ( FSI ) test do determine whether Insulin Resistance ( IR ) Type II Diabetes ( T2D ) . 1 . Diagnoses organic mood disorder , mood disorder otherwise specify , alcohol dependence T2D 2. presence rapid cycling ( Diagnostic Statistical Manual Mental Disorders ( DSM5 criterion ) , mania , ( indicated Young Mania Rating Scale [ YMRS ] score &gt; 15 ) , suicide ideation ( current score 5 Suicidal Ideation section ColumbiaSuicide Severity Rating Scale ( CSSRS ) 3. patient receive metformin &lt; 3 month prior study entry 4. metformin allergy sensitivity 5. metformin contraindicate liver function test &gt; three time upper limit normal ( alanine transaminase ( ALT ) &gt; 162 U/L , aspartate transaminase ( AST ) &gt; 69 U/L NSHA ) , estimate glomerular filtration rate ( eGFR ) &lt; 30 , complete blood count ( CBC ) reveal megaloblastic anemia preexist untreated B12 deficiency 6. pregnancy breastfeed 7. lactose intolerance , 8 ) patient lack full capacity consent study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>